Evidence map›Paper›PMID 36212599›Full record

ReviewWorld journal of clinical oncology2022

Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?

Mo-Xuan Wang, Shu-Yue Gao, Fan Yang, Run-Jia Fan, Qin-Na Yang, Tian-Lan Zhang, Nian-Song Qian, Guang-Hai Dai

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mo-Xuan WangDepartment of Oncology, Chinese PLA Medical School, Beijing 100853, China.
Shu-Yue GaoDepartment of Oncology, Chinese PLA Medical School, Beijing 100853, China.
Fan YangDepartment of Oncology, Chinese PLA Medical School, Beijing 100853, China.
Run-Jia FanDepartment of Oncology, Chinese PLA Medical School, Beijing 100853, China.
Qin-Na YangDepartment of Oncology, Chinese PLA Medical School, Beijing 100853, China.
Tian-Lan ZhangDepartment of Oncology, Chinese PLA Medical School, Beijing 100853, China.
Nian-Song QianDepartment of Oncology, Senior Department of Respiratory and Critical Care Medicine, The Eighth Medical Center of Chinese PLA General Hospital, Beijing 100853, China. kyotomed@foxmail.com.
Guang-Hai DaiDepartment of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
Chinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has shown great promise in treating various types of malignant tumors. However, some patients with gastrointestinal cancer have been known to experience rapid disease progression after treatment, a situation referred to as hyperprogressive disease (HPD). This minireview focuses on the definitions and potential mechanisms of HPD, natural disease progression in gastrointestinal malignancies, and tumor immunological microenvironment.

Indexed as

Colorectal cancerGastric cancerHyperprogressiveImmunotherapyNatural process

Identifiers

PMID36212599
PMCPMC9537503
OpenAlexW4296751057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.